CureVac (English Wikipedia)

"German government invests in the development of a vaccine". Website of the Federal Government | Bundesregierung. 17 June 2020. Archived from the original on 14 August 2023. Retrieved 14 August 2023.

cdc.gov

"Understanding mRNA COVID-19 vaccines". US Centers for Disease Control and Prevention. 18 December 2020. Archived from the original on 3 March 2021. Retrieved 5 January 2021.

clinicaltrials.gov

"A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults". ClinicalTrials.gov. 8 December 2020. NCT04652102. Archived from the original on 3 February 2021. Retrieved 19 December 2020.

clinicaltrialsregister.eu

"Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older". EU Clinical Trials Register. 19 November 2020. Archived from the original on 13 February 2021. Retrieved 5 January 2021. Proposed INN: zorecimeran

curevac.com

"CureVac Announces New Management Structure" (Press release). Curevac. Archived from the original on 21 June 2018. Retrieved 21 June 2018.
"Company Information". Curevac. Archived from the original on 27 November 2020. Retrieved 18 December 2020.
Sovereign (15 June 2020). "German Federal Government invests 300 Million Euros in CureVac". CureVac. Archived from the original on 14 August 2023. Retrieved 14 August 2023.
"CureVac Initiates Rolling Submission With European Medicines Agency (EMA) for COVID-19 Vaccine Candidate, CVnCoV". CureVac Website. 12 February 2021. Archived from the original on 1 March 2021. Retrieved 17 February 2021.
"CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV". curevac.com (Press release). 16 June 2021. Archived from the original on 24 June 2021. Retrieved 17 June 2021.

doi.org

Schlake, Thomas; Thess, Andreas; Fotin-Mleczek, Mariola; Kallen, Karl-Josef (2012). "Developing mRNA-vaccine technologies". RNA Biology. 9 (11): 1319–1330. doi:10.4161/rna.22269. ISSN 1547-6286. PMC 3597572. PMID 23064118.
Dolgin, Elie (18 June 2021). "CureVac COVID vaccine let-down spotlights mRNA design challenges". Nature. 594 (7864): 483. Bibcode:2021Natur.594..483D. doi:10.1038/d41586-021-01661-0. PMID 34145413. S2CID 235480198.
"Deutschland fällt weiter zurück". Kma - Klinik Management Aktuell. 10 (11): 62–63. November 2005. doi:10.1055/s-0036-1573504. ISSN 1439-3514. S2CID 257105518. Archived from the original on 2 February 2024. Retrieved 20 August 2022.

dx.doi.org

"Deutschland fällt weiter zurück". Kma - Klinik Management Aktuell. 10 (11): 62–63. November 2005. doi:10.1055/s-0036-1573504. ISSN 1439-3514. S2CID 257105518. Archived from the original on 2 February 2024. Retrieved 20 August 2022.

dw.com

"COVID-19 vaccine search: Germany buys stake in CureVac". Deutsche Welle. 15 June 2020. Archived from the original on 7 January 2021. Retrieved 5 January 2021.
"Germany and US wrestle over coronavirus vaccine: report". Deutsche Welle. Archived from the original on 15 March 2020. Retrieved 15 March 2020.

electrek.co

Lambert, Fred (10 November 2020). "Elon Musk: Tesla's RNA vaccine printer for CureVac is going to be 'important product for the world'". ElecTrek. Archived from the original on 2 February 2024. Retrieved 15 December 2021.

endpts.com

Carroll, John (18 October 2017). "Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines". endpts.com. Archived from the original on 7 April 2020. Retrieved 8 May 2018.

europa.eu

ema.europa.eu

"COVID-19 vaccines: studies for approval". Europa.eu. 2 December 2020. Archived from the original on 17 June 2021. Retrieved 17 June 2021.

fiercebiotech.com

"Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac". Fierce Biotech. 17 September 2014. Archived from the original on 8 December 2015. Retrieved 3 December 2015.
"Was it something he said? Biotech CEO who met Trump this month exits without a word". FierceBiotech. 12 March 2020. Archived from the original on 17 March 2020. Retrieved 15 March 2020.

fiercepharma.com

Blankenship, Kyle (2 July 2020). "Tesla teams up with CureVac to make 'RNA microfactories' for COVID-19 shot, Musk says". FiercePharma. Archived from the original on 15 December 2021. Retrieved 15 December 2021.

forbes.com

"Bill And Melinda Gates Foundation Makes Its Largest Ever Equity Investment In A Biotech Company". Forbes. Archived from the original on 17 March 2020. Retrieved 26 August 2017.

ft.com

Miller, Joe; Chazan, Guy; Cookson, Clive (15 June 2020). "Berlin to buy stake in Covid-19 vaccine player CureVac". Financial Times. Archived from the original on 14 August 2023. Retrieved 14 August 2023.
Solomon, Erika; Kuchler, Hannah (12 October 2021). "CureVac drops Covid vaccine to focus on new jab with GSK". Financial Times. Archived from the original on 14 August 2023. Retrieved 14 August 2023.

genengnews.com

"J&J's Janssen Companies Launch a Trio of Collaborations". 3 October 2013. Archived from the original on 23 May 2021. Retrieved 16 March 2020.
"CRI, Ludwig to Test Cancer Immunotherapy Combinations with CureVac". 4 November 2013. Archived from the original on 2 February 2024. Retrieved 16 March 2020.

harvard.edu

ui.adsabs.harvard.edu

Dolgin, Elie (18 June 2021). "CureVac COVID vaccine let-down spotlights mRNA design challenges". Nature. 594 (7864): 483. Bibcode:2021Natur.594..483D. doi:10.1038/d41586-021-01661-0. PMID 34145413. S2CID 235480198.

in-pharmatechnologist.com

"Curevac starts work on RNA-based drug plant with capacity for Lilly deal". in-pharmatechnologist.com. 30 October 2017. Archived from the original on 2 February 2024. Retrieved 15 January 2023.

marketwatch.com

Tomi Kilgore (14 August 2020). "CureVac's stock debuts at nearly triple the IPO price". MarketWatch. Archived from the original on 16 August 2020. Retrieved 15 August 2020.

nanalyze.com

"The 8 Biggest Startups in Europe by Funding - Nanalyze". Nanalyze. 3 October 2017. Archived from the original on 17 March 2020. Retrieved 18 May 2018.

nih.gov

pubmed.ncbi.nlm.nih.gov

Schlake, Thomas; Thess, Andreas; Fotin-Mleczek, Mariola; Kallen, Karl-Josef (2012). "Developing mRNA-vaccine technologies". RNA Biology. 9 (11): 1319–1330. doi:10.4161/rna.22269. ISSN 1547-6286. PMC 3597572. PMID 23064118.
Dolgin, Elie (18 June 2021). "CureVac COVID vaccine let-down spotlights mRNA design challenges". Nature. 594 (7864): 483. Bibcode:2021Natur.594..483D. doi:10.1038/d41586-021-01661-0. PMID 34145413. S2CID 235480198.

ncbi.nlm.nih.gov

Schlake, Thomas; Thess, Andreas; Fotin-Mleczek, Mariola; Kallen, Karl-Josef (2012). "Developing mRNA-vaccine technologies". RNA Biology. 9 (11): 1319–1330. doi:10.4161/rna.22269. ISSN 1547-6286. PMC 3597572. PMID 23064118.

pharmatimes.com

"CureVac, Sanofi Paster in 150m-euro-plus vaccines deal". 2 July 2014. Archived from the original on 12 April 2021. Retrieved 16 March 2020.

reuters.com

Szymanska, Zuzanna; Burger, Ludwig (12 October 2021). "CureVac drops COVID-19 vaccine, pins hope on next-generation shots". Reuters. Retrieved 14 August 2023.
Carrel, Paul; Rinke, Andreas (15 March 2020). "Germany tries to halt U.S. interest in firm working on coronavirus vaccine". Reuters. Archived from the original on 17 March 2020. Retrieved 15 March 2020.

uk.reuters.com

Aripaka, Pushkala; Schuetze, Arno (19 July 2020). "GSK buys 10% of CureVac in vaccine tech deal". Reuters. Archived from the original on 14 August 2020. Retrieved 21 July 2020.

science.org

Cohen, John (18 June 2021). "What went wrong with CureVac's highly anticipated new mRNA vaccine for COVID-19?". Science.org. Archived from the original on 14 August 2023. Retrieved 14 August 2023.

sciencemag.org

news.sciencemag.org

"German RNA Vaccines Company Bags €2 Million E.U. Vaccine Prize". 12 March 2014. Archived from the original on 5 March 2015. Retrieved 3 December 2015.

semanticscholar.org

api.semanticscholar.org

Dolgin, Elie (18 June 2021). "CureVac COVID vaccine let-down spotlights mRNA design challenges". Nature. 594 (7864): 483. Bibcode:2021Natur.594..483D. doi:10.1038/d41586-021-01661-0. PMID 34145413. S2CID 235480198.
"Deutschland fällt weiter zurück". Kma - Klinik Management Aktuell. 10 (11): 62–63. November 2005. doi:10.1055/s-0036-1573504. ISSN 1439-3514. S2CID 257105518. Archived from the original on 2 February 2024. Retrieved 20 August 2022.

telegraph.co.uk

Ludwig Burger (6 January 2021). "CureVac strikes COVID-19 vaccine alliance with Bayer". Reuters. Archived from the original on 1 August 2020. Retrieved 7 January 2021.

twitter.com

CureVac (16 March 2020). "(Untitled)". Twitter. Archived from the original on 16 March 2020. Retrieved 16 March 2020.

vaccinenewsdaily.com

"IAVI and CureVac partner to further AIDS vaccine candidates". Archived from the original on 8 October 2015. Retrieved 3 December 2015.

web.archive.org

"CureVac Announces New Management Structure" (Press release). Curevac. Archived from the original on 21 June 2018. Retrieved 21 June 2018.
"Company Information". Curevac. Archived from the original on 27 November 2020. Retrieved 18 December 2020.
Miller, Joe; Chazan, Guy; Cookson, Clive (15 June 2020). "Berlin to buy stake in Covid-19 vaccine player CureVac". Financial Times. Archived from the original on 14 August 2023. Retrieved 14 August 2023.
Sovereign (15 June 2020). "German Federal Government invests 300 Million Euros in CureVac". CureVac. Archived from the original on 14 August 2023. Retrieved 14 August 2023.
"German government invests in the development of a vaccine". Website of the Federal Government | Bundesregierung. 17 June 2020. Archived from the original on 14 August 2023. Retrieved 14 August 2023.
Cohen, John (18 June 2021). "What went wrong with CureVac's highly anticipated new mRNA vaccine for COVID-19?". Science.org. Archived from the original on 14 August 2023. Retrieved 14 August 2023.
Solomon, Erika; Kuchler, Hannah (12 October 2021). "CureVac drops Covid vaccine to focus on new jab with GSK". Financial Times. Archived from the original on 14 August 2023. Retrieved 14 August 2023.
Carroll, John (18 October 2017). "Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines". endpts.com. Archived from the original on 7 April 2020. Retrieved 8 May 2018.
Aripaka, Pushkala; Schuetze, Arno (19 July 2020). "GSK buys 10% of CureVac in vaccine tech deal". Reuters. Archived from the original on 14 August 2020. Retrieved 21 July 2020.
"CureVac Opens up an mRNA Hub in Moderna's Cambridge Backyard". 10 September 2015. Archived from the original on 23 May 2020. Retrieved 3 December 2015.
"COVID-19 vaccine search: Germany buys stake in CureVac". Deutsche Welle. 15 June 2020. Archived from the original on 7 January 2021. Retrieved 5 January 2021.
"CureVac GmbH erhält Innovationspreis des Lands Baden-Württemberg". www.bionity.com (in German). Archived from the original on 22 April 2022. Retrieved 22 April 2022.
. 23 February 2016 https://web.archive.org/web/20160223142545/https://www.wissensfabrik-deutschland.de/portal/streamer?fid=544880. Archived from the original on 23 February 2016. Retrieved 22 April 2022. {{cite web}}: Missing or empty |title= (help)
"J&J's Janssen Companies Launch a Trio of Collaborations". 3 October 2013. Archived from the original on 23 May 2021. Retrieved 16 March 2020.
"CRI, Ludwig to Test Cancer Immunotherapy Combinations with CureVac". 4 November 2013. Archived from the original on 2 February 2024. Retrieved 16 March 2020.
"German RNA Vaccines Company Bags €2 Million E.U. Vaccine Prize". 12 March 2014. Archived from the original on 5 March 2015. Retrieved 3 December 2015.
"CureVac, Sanofi Paster in 150m-euro-plus vaccines deal". 2 July 2014. Archived from the original on 12 April 2021. Retrieved 16 March 2020.
"Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac". Fierce Biotech. 17 September 2014. Archived from the original on 8 December 2015. Retrieved 3 December 2015.
"Bill And Melinda Gates Foundation Makes Its Largest Ever Equity Investment In A Biotech Company". Forbes. Archived from the original on 17 March 2020. Retrieved 26 August 2017.
"IAVI and CureVac partner to further AIDS vaccine candidates". Archived from the original on 8 October 2015. Retrieved 3 December 2015.
"CureVac Opens up an mRNA Hub in Moderna's Cambridge Backyard Xconomy". Xconomy. 10 September 2015. Archived from the original on 23 May 2020. Retrieved 9 June 2017.
"Curevac starts work on RNA-based drug plant with capacity for Lilly deal". in-pharmatechnologist.com. 30 October 2017. Archived from the original on 2 February 2024. Retrieved 15 January 2023.
Blankenship, Kyle (2 July 2020). "Tesla teams up with CureVac to make 'RNA microfactories' for COVID-19 shot, Musk says". FiercePharma. Archived from the original on 15 December 2021. Retrieved 15 December 2021.
Lambert, Fred (10 November 2020). "Elon Musk: Tesla's RNA vaccine printer for CureVac is going to be 'important product for the world'". ElecTrek. Archived from the original on 2 February 2024. Retrieved 15 December 2021.
"The 8 Biggest Startups in Europe by Funding - Nanalyze". Nanalyze. 3 October 2017. Archived from the original on 17 March 2020. Retrieved 18 May 2018.
Tomi Kilgore (14 August 2020). "CureVac's stock debuts at nearly triple the IPO price". MarketWatch. Archived from the original on 16 August 2020. Retrieved 15 August 2020.
"Was it something he said? Biotech CEO who met Trump this month exits without a word". FierceBiotech. 12 March 2020. Archived from the original on 17 March 2020. Retrieved 15 March 2020.
"Germany and US wrestle over coronavirus vaccine: report". Deutsche Welle. Archived from the original on 15 March 2020. Retrieved 15 March 2020.
Carrel, Paul; Rinke, Andreas (15 March 2020). "Germany tries to halt U.S. interest in firm working on coronavirus vaccine". Reuters. Archived from the original on 17 March 2020. Retrieved 15 March 2020.
CureVac (16 March 2020). "(Untitled)". Twitter. Archived from the original on 16 March 2020. Retrieved 16 March 2020.
"Understanding mRNA COVID-19 vaccines". US Centers for Disease Control and Prevention. 18 December 2020. Archived from the original on 3 March 2021. Retrieved 5 January 2021.
"Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older". EU Clinical Trials Register. 19 November 2020. Archived from the original on 13 February 2021. Retrieved 5 January 2021. Proposed INN: zorecimeran
"A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults". ClinicalTrials.gov. 8 December 2020. NCT04652102. Archived from the original on 3 February 2021. Retrieved 19 December 2020.
Ludwig Burger (6 January 2021). "CureVac strikes COVID-19 vaccine alliance with Bayer". Reuters. Archived from the original on 1 August 2020. Retrieved 7 January 2021.
"CureVac Initiates Rolling Submission With European Medicines Agency (EMA) for COVID-19 Vaccine Candidate, CVnCoV". CureVac Website. 12 February 2021. Archived from the original on 1 March 2021. Retrieved 17 February 2021.
"CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV". curevac.com (Press release). 16 June 2021. Archived from the original on 24 June 2021. Retrieved 17 June 2021.
"COVID-19 vaccines: studies for approval". Europa.eu. 2 December 2020. Archived from the original on 17 June 2021. Retrieved 17 June 2021.
"Deutschland fällt weiter zurück". Kma - Klinik Management Aktuell. 10 (11): 62–63. November 2005. doi:10.1055/s-0036-1573504. ISSN 1439-3514. S2CID 257105518. Archived from the original on 2 February 2024. Retrieved 20 August 2022.

wissensfabrik-deutschland.de

. 23 February 2016 https://web.archive.org/web/20160223142545/https://www.wissensfabrik-deutschland.de/portal/streamer?fid=544880. Archived from the original on 23 February 2016. Retrieved 22 April 2022. {{cite web}}: Missing or empty |title= (help)

worldcat.org

Schlake, Thomas; Thess, Andreas; Fotin-Mleczek, Mariola; Kallen, Karl-Josef (2012). "Developing mRNA-vaccine technologies". RNA Biology. 9 (11): 1319–1330. doi:10.4161/rna.22269. ISSN 1547-6286. PMC 3597572. PMID 23064118.
"Deutschland fällt weiter zurück". Kma - Klinik Management Aktuell. 10 (11): 62–63. November 2005. doi:10.1055/s-0036-1573504. ISSN 1439-3514. S2CID 257105518. Archived from the original on 2 February 2024. Retrieved 20 August 2022.

xconomy.com

"CureVac Opens up an mRNA Hub in Moderna's Cambridge Backyard". 10 September 2015. Archived from the original on 23 May 2020. Retrieved 3 December 2015.
"CureVac Opens up an mRNA Hub in Moderna's Cambridge Backyard Xconomy". Xconomy. 10 September 2015. Archived from the original on 23 May 2020. Retrieved 9 June 2017.